Bayer registered a new indication for rivaroxaban for use in patients with coronary heart disease or peripheral artery disease in the European Union and USA

Bayer Company Press Release

Rational Pharmacotherapy in Cardiology
Racionalʹnaâ farmakoterapiâ v kardiologii

eng | рус

User

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)

Rational Pharmacotherapy in Cardiology

Advanced search

Archives

Download this PDF file

Fullscreen

For citations:

Press Release B. Bayer registered a new indication for rivaroxaban for use in patients with coronary heart disease or peripheral artery disease in the European Union and USA. Rational Pharmacotherapy in Cardiology. 2018;14(5):797. (In Russ.)

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)

Username
Password
	Remember me

User

Rational Pharmacotherapy in Cardiology

For citations:

Cookies policy